Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

• Главные авторы: Lisa D. MacDonald (Автор), Alecia MacKay (Автор), Valarmathy Kaliaperumal (Автор), Genevieve Weir (Автор), Andrea Penwell (Автор), Rajkannan Rajagopalan (Автор), Joanne M. Langley (Автор), Scott Halperin (Автор), Marc Mansour (Автор), Marianne M. Stanford (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodo...